Charles Nakar

Get to know Dr. Nakar

Dr. Nakar is a board-certified Pediatric Hematologist-Oncologist at the Indiana Hemophilia and Thrombosis Center (IHTC).

Education & Training

Ben-Gurion University | M.D.

Cohen Children’s Medical Center | Residency

Memorial Sloan Kettering Cancer Center | Pediatric Hematology-Oncology Fellowship

Cornell University | Pediatric Hematology-Oncology Fellowship

Certifications & Licensure

Indiana State Medical License

American Board of Pediatrics, General Pediatrics

American Board of Pediatrics, Hematology-Oncology

Societies & Honors

International Society on Thrombosis and Haemostasis

Expertise & Special Interests

Bleeding disorders with special interest in hemophilia, surgical hemostasis and outcomes, inhibitor detection and eradication

Platelet and rare coagulation disorders including plasminogen deficiency

HVLM Clinic: for patients with hemangiomas, vascular and lymphatic malformations

Pediatric thrombosis

Hemolytic anemias and other red blood cell disorders

Hospital Affiliations

St. Vincent Hospital, Indianapolis

St. Vincent Hospital, Carmel

St. Vincent Hospital, Fishers

St. Vincent Seton Specialty Hospital

St. Vincent Heart Center

Indiana University Health Riley Children’s Hospital

Indiana University Health North

Indiana University Health Methodist Hospital

Indiana University Health Saxony Hospital

Indiana University Health Morgan Hospital

Publications

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10. Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM.

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatr Blood Cancer. 2016 Oct;63(10):1822-8. doi: 10.1002/pbc.26082. Epub 2016 May 27. Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL.

Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015 May;21(3):365-73. doi: 10.1111/hae.12608. Epub 2015 Jan 11. Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, Chong Y, Blades T, Shapiro A.

More publications by Dr. Nakar

A short interview with Dr. Nakar

What do you like about IHTC and its approach to care?

Our comprehensive approach to patient care, both in traditional patient care and in our approaches to life stage transitions. In addition, as a pediatric hematologist, it’s wonderful to watch my patients transition to an adult hematologist within the center. Our transition programs allow for great communication, education and care.

What aspects of your work are you the most passionate about?

It’s a passion of mine to help educate patients and families to lead successful lives in spite of their spectrum of health challenges.

How would you describe your approach to patient care?

Understanding the needs of both the patient and family is critical to patient care. With our multidisciplinary team, we’re able to address patient needs holistically by assisting with issues—such as insurance and career counseling—so they can focus on getting better.

Charles Nakar, MD